Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma

 
• By Ian Schofield
  
Lung radiography
An orphan drug for mesothelioma is one of two products withdrawn from the CHMPassessment process
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet